Pembrolizumab improves outcomes in high-risk bladder cancer
网页6 天之前 · NCI Press Office. 240-760-6600. Adjuvant pembrolizumab helps people with muscle-invasive bladder cancer remain cancer-free longer than observation alone. Credit: Terese Winslow/National Cancer Institute. Results from a large clinical trial show that treatment with an immunotherapy drug may nearly …
FDA Approves Pembrolizumab with Chemotherapy for …
网页3 天之前 · On 17 September 2024, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) with pemetrexed and platinum chemotherapy as first-line treatment of unresectable advanced or metastatic malignant pleural mesothelioma (MPM). Efficacy was investigated in KEYNOTE-483 (NCT02784171), a randomised, open-label study in patients ...
FDA approves pembrolizumab with chemotherapy for …
网页5 天之前 · Patients were randomized (1:1) to receive either pembrolizumab for up to 2 years in combination with pemetrexed and platinum-based chemotherapy for up to 6 cycles (n=222) or pemetrexed and ...
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before …
网页2024年9月15日 · RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first-time presentation of overall survival (OS) results from the Phase 3 KEYNOTE-522 trial evaluating KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single ...
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative …
网页2022年7月20日 · Pembrolizumab monotherapy has shown durable antitumor activity in advanced triple-negative breast cancer, 6-9 particularly as first-line therapy, with improved clinical responses observed among...
FDA approves neoadjuvant/ adjuvant pembrolizumab for …
网页On October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of...
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of ... - Merck
网页2021年7月27日 · FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery. Save. July 27, 2021 6:30 am ET.
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell …
网页2023年6月3日 · Among patients with resectable, early-stage NSCLC, neoadjuvant pembrolizumab plus chemotherapy followed by resection and adjuvant pembrolizumab significantly improved event-free survival, major...
FDA approves pembrolizumab for high-risk early-stage triple …
网页On July 26, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for high-risk, early-stage, triple-negative breast cancer (TNBC) in combination with chemotherapy...
Immunotherapy after surgery helps people with high-risk bladder …
网页6 天之前 · After a median follow-up of almost four years, patients in the pembrolizumab group remained cancer-free for a median of 29.6 months, compared with 14.2 months for the observation group. Pembrolizumab was well tolerated, with the most common side effects being fatigue, itching, diarrhea, and an underactive thyroid.
跳至内容